U.S. FTC clears Valeant deal for Medicis Pharmaceutical
(Reuters) - The U.S. Federal Trade Commission has cleared Valeant Pharmaceuticals International Inc's (VRX.TO) $2.6 billion deal to buy U.S. dermatology rival Medicis Pharmaceutical Corp MRX.N, without conditions, Valeant said on Friday.
The combined company is set to dominate the U.S. dermatology market. Medicis led that market in gross sales in 2011, while Valeant, Canada's biggest public drugmaker, ranked third, Valeant said when the deal was first announced.
Last December, when the FTC approved Valeant's acquisitions of the dermatology units of Sanofi (SASY.PA) and Johnson & Johnson (JNJ.N), it forced the firm to sell off the rights to three drugs.
Valeant, on the acquisition trail since its 2010 takeover by Biovail Corp, which assumed the Valeant name, has favored segments where patients often pay out of pocket, such as ophthalmology and dermatology, cutting its exposure to cost-sensitive insurers.
Medicis' products include Solodyn, a prescription acne tablet, Restylane, an injectable filler, and Dysport, a competitor to Allergan Inc's (AGN.N) Botox anti-wrinkle treatment. (Reporting by Allison Martell; editing by John Wallace)
SYDNEY - Asian markets were finding their feet on Tuesday after a rocky ride the previous session, though uncertainty about the true state of China's economy kept nerves frayed and commodity prices restrained.
- U.S. small businesses borrowed more money in January than they did a year earlier, signaling continued growth in the economy despite a spate of cold weather that has been blamed for weakness in many other indicators of activity.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.